Lecanemab is the first medication approved in Canada that targets the buildup of amyloid plaque in the brain, which is ...
Lecanemab, as the drug is known, was approved by Health Canada this week. It is the first treatment available in Canada to ...
The NDA submission is supported by data from two pivotal Phase 3 clinical trials, which evaluated MK-6240’s performance in detecting tau pathology in early Alzheimer’s disease. These studies met their ...
A gentle flicker of light and a steady hum of sound might help slow the course of Alzheimer’s disease. That’s the idea behind ...
A new drug to treat Alzheimer’s Disease has been approved by Health Canada and it is the first drug that targets an ...
Health Canada recently authorized use of lecanemab, but experts say the drug is an incremental benefit, not a cure ...
The Canadian Press on MSN
Health Canada authorizes long-awaited drug to slow early-stage Alzheimer's disease
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer's disease. Lecanemab is the first ...
Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
A Southport cancer survivor and a Florida man fighting Alzheimer's are among inspiring athletes competing in Saturday's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback